Novo Nordisk A/S | NOVOB - Cash And Equivalent


Novo Nordisk A/S reported DKK18.44B in Cash and Equivalent for its fiscal quarter ending in June of 2025.





Cash And Equivalent Change Date
Bausch Health Companies USD 1.31B 419M Sep/2025
Bristol-Myers Squibb USD 10.21B 5.52B Dec/2025
Eli Lilly USD 7.27B 2.52B Dec/2025
GlaxoSmithKline GBP 3.3B 303M Sep/2025
Merck USD 18.17B 10.16B Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Novo Nordisk DKK 38.94B 24.15B Mar/2025
Novo Nordisk A/S DKK 18.44B 5.78B Jun/2025
Pacira USD 147.59M 152.89M Sep/2025
Sanofi EUR 7.66B 1.25B Dec/2025
Supernus Pharmaceuticals USD 151.37M 6.66M Sep/2025